27 OCT 2023 | US | Sanofi to Spin-Off Consumer Business and Focus on Biopharma by End Q4 2023 Sanofi announced that it...
BioBlast w/e 27 Oct 23
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
BioBlast w/e 23 Oct 23
23 OCT 2023 | US | Approval Alert: FDA Approves Celltrion’s Zymfentra® (infliximab-dyyb), Biosimilar to Janssen’s...
BioBlast w/e 15 Oct 23
15 OCT 2023 | Samsung Bioepis Reveals SB16 (denosumab) Study Results at ASBMR Samsung Bioepis presented new data on...
Advanta succeeds again in second extension of time application opposed by Nufarm
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Breakthrough Mining Innovator Globaltech wins AU Patent Battle against Market Leader Reflex
An Australian Court has found in favour of Globaltech which solved a mining problem with an elegant solution. An important lesson from this decision is that driving IP innovation can be central to maintaining a market-leading position.
BioBlast w/e 07 Oct 23
07 OCT 2023 | Samsung Bioepis Presents Switching Study Results for SB15, Biosimilar to Regeneron’s Eylea®...
When perceiving the problem is the inventive step – complacent market leader Reflex infringes disruptor Globaltech’s valid patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 02 Oct 23
02 OCT 2023 | Nobel Prize Awarded to Katalin Karikó and Drew Weissman for Their Work Which Supported the mRNA COVID-19...
Zoetis Vaccine Patent Survives Opposition Appeal by the Hair of its Chinny Chin Chin
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 22 Sep 23
22 SEP 2023 | KR | Prestige Biologics Partners with Dr. Reddy’s Laboratories Subsidiary in Strategic Manufacturing...
BioBlast w/e 15 Sep 23
15 SEP 2023 | US | Novartis Shareholders Approve Sandoz Spin-Off On 15 September 2023, Novartis shareholders approved...
Federal Court Shines Light on Patent Litigation Case Management
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 08 Sep 23
08 SEP 2023 | Coherus Completes Acquisition Of Surface Oncology Coherus Biosciences announced that it completed its...
No Anshun Estoppel in Fourth VMS Validity Challenge
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 01 Sep 23
01 SEP 2023 | AU | Celltrion Submits Marketing Application For CT-P43, Biosimilar To Janssen’s Stelara® (Ustekinumab)...
BioBlast w/e 25 Aug 23
25 AUG 2023 | US | Celltrion and J&J Reach Patent Settlement Regarding Ustekinumab Korea Biomedical...